You are here

Drug safety update: Hyoscine butylbromide (Buscopan)

9 May, 2017
Buscopan

The Government has provided an important update on Hyoscine butylbromide (Buscopan):

“We have received reports of patients who have died after receiving hyoscine butylbromide injection (including a report from a coroner). In most of these cases, the fatal adverse reaction was reported as acute myocardial infarction or cardiac arrest.”

Advice for healthcare professionals:

  • hyoscine butylbromide injection can cause serious adverse effects including tachycardia, hypotension, and anaphylaxis
  • these adverse effects can result in a fatal outcome in patients with underlying cardiac disease, such as those with heart failure, coronary heart disease, cardiac arrhythmia, or hypertension
  • hyoscine butylbromide injection should be used with caution in patients with cardiac disease
  • monitor these patients, and ensure that resuscitation equipment, and personnel who are trained how to use this equipment, are readily available
  • hyoscine butylbromide injection remains contraindicated in patients with tachycardia

Suspected adverse reactions should be reported on a Yellow Card. Article citation: Drug Safety Update volume 10 issue 7, February 2017:1.

Find out more

Content tools

Accessibility controls

Text size

AA A

Colour